We can’t show the full text here under this license. Use the link below to read it at the source.
The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD
New Potential of Glucagon-like Peptide-1 Receptor Agonists to Treat Fatty Liver Disease
AI simplified
Abstract
The FDA approved semaglutide for obesity management in 2021.
- Cirrhosis from nonalcoholic fatty liver disease (NAFLD) is becoming increasingly common in the United States.
- Endocrinologists may miss diagnosing NAFLD in adults with obesity or type 2 diabetes mellitus, who are at the highest risk.
- Recent studies indicate that glucagon-like peptide-1 receptor agonists (GLP-1RAs) may be beneficial for treating nonalcoholic steatohepatitis () in these patients.
- Multidisciplinary teams led by endocrinologists are essential for implementing screening and treatment guidelines for NAFLD.
- Current pharmacological treatment options for NAFLD are limited to vitamin E for non-diabetic patients and diabetes medications, including GLP-1RAs, that reverse steatohepatitis.
AI simplified
Key numbers
39%
resolution rate
Resolution of in patients treated with liraglutide vs. placebo.
19% to 32%
Liver fat reduction range
Percentage reduction in liver fat content observed with treatment.
70%
Prevalence of NAFLD in T2D
Percentage of T2D patients found to have NAFLD.